1 . The anti-hypertensive effect of converting enzyme inhibition was evaluated in twenty-three hypertensive patients (seven renovascular, four essential, four malignant, one scleroderma, three chronic renal failure, four primary or idiopathic aldosteronism).
Introduction
Recently, a nonapeptide inhibitor of the enzyme converting angiotensin I into angiotensin I1 was discovered (Ondetti, Williams, Sabo, Flusced, Weaver & Kocy, 1971) Squibb Laboratories). This, along with a competitive inhibitor of angiotensin 11, has provided a new approach in assessing the role of the reninangiotensin system and its interaction with the sodium ion in the pathogenesis and maintenance of hypertension. In the present work, we investigate the effects of this compound on the blood pressure of patients with different types of hypertensive disease.
Method
Twenty-three hypertensive patients, aged 14-59 years, were studied. All had been off anti-hypertensive medication for at least 3 weeks before the study and were maintained on a constant salt intake of 87 mequiv./day. The diagnostic work-up included measurement of plasma and urine electrolytes, blood urea nitrogen concentration, creatinine clearance, screening for phaeochromocytoma, rapidsequence intravenous pyelogram and renal arteriography .
Renin activity and aldosterone were measured by radioimmunoassay in plasma obtained with the patient upright for the initial classification and supine, immediately before and 4-6 h after administration of the inhibitor SQ 20881. Blood pressures were monitored at 2 or 5 min intervals with an automatic blood pressure recorder (Arteriosonde 1216, Roche).
The nonapaptide was diluted in 5 % dextrose to 12.5 mg/ml and slowly injected into the antecubital vein over a period of 5 min at increasing doses of 0.25, 0.5, 1 .O 2.0 and 4 mg/kg. It was readministered only after the blood pressure had returned to control values or had remained unchanged for a period of at least 2 h.
In six patients who showed only partial response, sodium depletion was then induced by low sodium diet (10 mequiv./day) for 48 h and the administration 
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of a diuretic. Urinary sodium excretion was measured daily and cumulative losses were calculated. Subsequently, a single dose (2 or 4 mglkg) of the nonapeptide was injected. This latter dose was always equivalent to the highest dose administered before sodium depletion.
Results

Blood pressure
In sixteen of the twenty-three patients, inhibition of converting enzyme induced a reduction in blood pressure (see Table 1 ). Blood pressure fall started within minutes after administration of the inhibitor intravenously and was complete within 1-2 h. Maximal blood pressure reduction was always achieved with a dose of 1 mg/kg and further increase up to 4 mg/kg only prolonged the duration of the blood pressure response.
In all seven patients with renovascular hypertension converting-enzyme inhibition induced a substantial fall in blood pressure from a mean of 180/123 ( f 4/6) to 137/92 ( & 6/5) mmHg (mean f SE) (P<O.oOl).
The four patients with malignant hypertension all exhibited striking blood pressure reductions from 222/151 ( + 6 / 5 ) to 172/107 (+7/5) mmHg (P< 0.05).
Three patients with essential hypertension responded partially to the drug with a decrease from 186/121 (+5/7) to 166/105 ( f 8 / 4 ) mmHg.
Of the three patients with chronic renal failure and hypertension, only one exhibited some reduction from 180/130 to 1601115 mmHg. None of the patients with idiopathic aldosteronism showed a blood pressure response.
Potentiation of the anti-hypertensive response to converting enzyme blockade by sodium depletion
Six patients were studied twice, first while on a regular sodium intake and again during sodium depletion. Administration of the inhibitor (2-4 mglkg) initially produced a mean fall in blood pressure to only 161/107 (&6/4) mmHg. Subsequent sodium depletion resulted in a negative sodium balance of 178.6 2 35.4 mequiv. of Na + . Despite this, blood pressure did not change significantly (from 198/135 +7/4 to 188/133 f 5/2). However, readministration of the inhibitor at exactly the same dose as before now produced a significantly greater fall in blood pressure, to a mean value of 134/93 ( &6/3) mmHg.
Eflect of drug on plasma renin activity and plusina aldosterone
Out of nineteen patients studied, plasma renin activity values were increased by the drug in sixteen. In two patients with pseudoprimary aldosteronism renin activities fell and in one they remained unaltered. In contrast, plasma aldosterone concentrations, which were measured in eight patients, were found to be reduced in all but the two patients with idiopathic aldosteronism, in whom they were increased ( Table 1) .
Discussion
The present study indicates that blockade of angiotensin I-converting enzyme had a potent antihypertensive effect in sixteen of twenty-three hypertensive patients. This effect was noticed mainly in renovascular, essential and malignant hypertension and that due to generalized scleroderma with kidney involvement. Little or no response was seen in hypertension associated with chronic renal failure. No response at all was recorded in primary or idiopathic hyperaldosteronism. This blood pressurelowering effect of the blocking agent is in close agreement with earlier findings in animals and man with use of a competitive inhibitor of angiotensin 11 (Gavras, Brunner, Vaughan & Laragh, 1973 ; Brunner, Gavras, Laragh & Keenan, 1973) , the main difference being that the latter was only effective in patients with high renin activities whereas in the present study five out of eight patients with normal renin had also a significant response. None of the low-renin-activity patients showed any response. Plasma renin activity increased during converting enzyme blockade in all but three patients with pseudoprimary aldosteronism. In contrast, plasma aldosterone concentration decreased in all but two patients with idiopathic aldosteronism and one patient with essential hypzrtension. In six patients with a partial response of blood pressure, readministration of the inhibitor after sodium depletion (which in itself did not affect blood pressure, perhaps because of compensatory renin release) produced a significantly greater response. Thus a relatively small change in total body sodium was associated with a marked increase in the anti- hypertensive effectiveness. It appears therefore that in patients in whom both volume and vasoconstrictor factors are operative in sustaining the hypertension (Laragh, 1973) , elimination of one factor may not be sufficient.
In this context the converting-enzyme blockade can be a guide for the choice of more specific drug therapy (renin suppressing, or salt-eliminating or a combination thereof). Its prolonged action, ease of administration and lack of toxicity make it suitable for treating hypertensive emergencies in which a high renin activity is expected. It can also be useful for evaluating surgical curability of renovascular hypertension since the nonapeptide-induced blood pressure response may be able to predict the fall expected with successful vascular repair. Indeed one patient whose blood pressure was returned to normal by the drug was subsequently cured by renal artery repair.
In conclusion, these studies indicate that converting-enzyme inhibition can provide diagnostic and therapeutic information for a given hypertensive state and can be valuable for safely and efficiently treating certain hypertensive emergencies.
